Carcinoma, Bronchogenic  >>  Tecentriq (atezolizumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tecentriq (atezolizumab) / Roche
NCT01846416 / 2013-000177-69: A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]

Checkmark IASLC-WCLC 2015
Aug 2015 - Aug 2015: IASLC-WCLC 2015
Checkmark From FIR trial for advanced mNSCLC
May 2015 - May 2015: From FIR trial for advanced mNSCLC
Completed
2
138
US, Europe
Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody
Genentech, Inc.
Non-Small Cell Lung Cancer
01/15
12/17
NCT02495636: Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer

Withdrawn
2
0
US
CDX-1401, MPDL3280A
Yale University
Non-Small Cell Lung Cancer
07/17
07/17
NCT02748889: Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer

Not Appicable Oct 2016 - Oct 2016 : In SCLC at ESMO 2016 (Trial terminated)
Terminated
1/2
1
US
Carboplatin, Paraplatin, Etoposide, VP-16, Toposar, MPDL3280A, Atezolizumab
Giuseppe Giaccone, Vanderbilt University, Memorial Sloan Kettering Cancer Center
Small Cell Lung Cancer ( SCLC )
05/17
05/17

Download Options